{"nctId":"NCT00597753","briefTitle":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","startDateStruct":{"date":"2007-09"},"conditions":["Chronic Renal Failure","Chronic Kidney Disease","Anemia"],"count":803,"armGroups":[{"label":"Peginesatide","type":"EXPERIMENTAL","interventionNames":["Drug: peginesatide"]},{"label":"Epoetin alfa","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Epoetin Alfa"]}],"interventions":[{"name":"peginesatide","otherNames":["Omontys","Hematide","AF37702 Injection"]},{"name":"Epoetin Alfa","otherNames":["Epogen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to randomization.\n2. On intravenous epoetin alfa maintenance therapy continuously prescribed for a minimum of 8 weeks prior to randomization.\n3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the screening period\n\nExclusion Criteria\n\n1. Females who are pregnant or breast-feeding.\n2. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule or to all parenteral iron supplementation products.\n3. Known bleeding or coagulation disorder.\n4. Known hematologic disease or cause of anemia other than renal disease\n5. Poorly controlled hypertension\n6. Evidence of active malignancy within one year prior to randomization.\n7. Temporary (untunneled) dialysis access catheter.\n8. A scheduled kidney transplant\n9. A scheduled surgery that may be expected to lead to significant blood loss.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in Hemoglobin Between Baseline and the Evaluation Period","description":"The baseline hemoglobin value is defined as the mean of five hemoglobin values: the four most recent hemoglobin values taken prior to the day of randomization and the value obtained on the day of randomization. The mean hemoglobin during the Evaluation Period for each participant is calculated as the mean of the available hemoglobin values during study Weeks 29 through 36.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.30","spread":"0.523"},{"groupId":"OG001","value":"11.32","spread":"0.493"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.06","spread":"0.932"},{"groupId":"OG001","value":"11.25","spread":"0.846"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.956"},{"groupId":"OG001","value":"-0.09","spread":"0.922"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.103","spread":null},{"groupId":"OG001","value":"0.086","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.630","spread":null},{"groupId":"OG001","value":"0.717","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":304,"n":524},"commonTop":["Cough","Nausea","Dyspnoea","Diarrhoea","Arteriovenous fistula site complication"]}}}